Vadodara: A 28-year-old labour working at the Panelav unit of Alembic Pharmaceuticals Ltd fell unconscious on Saturday evening and later died at a hospital.
The worker identified as Prakash Baria, a resident of Halol taluka, was initially treated at the clinic of the company and then rushed to the Bhailal Amin General Hospital (BAGH). He was declared dead at the hospital. It is yet not clear what happened to Baria.
The family of the man, including her wife, insisted that the body should be taken to the plant to demand justice. The police did not allow this and eventually, the family agreed to go to the unit without the body.
Rhizen Pharma gets USFDA accelerated nod for Partnered Asset Umbralisib adult patients with Relapsed or Refractory MZL & FL medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib
February 09, 2021
In a first, Indian scientists develop oral drug for relapsed or refractory MZL, FL
In a major breakthrough in cancer treatment, Alembic Pharmaceutical’s co-owned Rhizen Pharmaceuticals has received US drug regulator - US Food and Drug Administration (USFDA)’s approval for novel next generation oral inhibitor of phosphoinositide 3 kinase (PI3K) delta - Umbralisib for treatment of relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL).
Umbralisib will be marketed by Nasdaq-listed TG Therapeutics, which led its clinical development, under the brand name of Ukoniq. Rhizen Pharmaceuticals co-owned by Alembic Pharmaceuticals with 50 per cent% stake and the rest by Dr Swaroop Vakkalanka, who is President & CEO of the company.
(1)
Umbralisib (UKONIQ) granted accelerated approval by US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL).
Umbralisib, a novel next generation inhibitor of PI3K delta CK1 epsilon, was discovered by Rhizen Pharmaceuticals and subsequently licensed to TG Therapeutics, who led the asset s clinical development.
Rhizen and its affiliate Alembic Pharma to support TG Therapeutics towards UKONIQ s commercialization as its manufacturing supply partner; Rhizen plans to register and commercialize Umbralisib in India.
Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ:TGTX), has secured US FDA accelerated approval for the treatment of: